Iambic Therapeutics is maintaining the momentum generated by its recent megaround and Big Pharma partnerships by gearing up ...

China is aiming to account for at least 25% of first-in-class drugs as part of a five-year push to cement its emerging status as a hotbed for innovative R&D. | China is aiming to account for at least ...

Following Takeda’s historic approval of the first orexin agonist with its narcolepsy treatment Orzeyful, Alkermes has followed up with pioneering data that looks to take the hyped drug class out of ...

President Donald Trump is attempting to seize further control of funding decisions made by the National Institutes of Health. | President Donald Trump is attempting to seize further control of funding ...

Eli Lilly-backed TRex Bio and hypertension-focused Retension Pharmaceuticals are the latest biotechs to set out plans to go ...

Beacon Therapeutics has found the light in a rare vision loss disease that has left larger companies in the dark. | Beacon Therapeutics has found the light in a rare vision loss disease that has left ...

Telix has struck a deal to buy ITM Isotope Technologies Munich | Telix has struck a deal to buy ITM Isotope Technologies Munich for $1.65 billion upfront, securing an R&D pipeline led by a rival to ...

A midstage study of Cue Biopharma’s hives drug candidate has hit its primary endpoint, emboldening the biotech to move the would-be challenger to Xolair into a phase 2b/3 trial.

Bristol Myers Squibb has axed the degrader-antibody conjugate (DAC) it bought from Orum Therapeutics for $100 million, ...

A new biotech has sprung out of stealth with a bold vision to develop the “greatest therapeutic of all time”—a drug that can ...

GSK has bet up to $750 million on a Chimagen Biosciences trispecific T-cell engager, positioning the Big Pharma to start ...

The company has voluntarily stopped enrolling new patients in the studies in response to reports of mostly mild or moderate ...